• ISSN 1674-8301
  • CN 32-1810/R
Volume 36 Issue 6
Nov.  2022
Turn off MathJax
Article Contents
Mingzi Zhang, Qi Li, Yehong Sun. Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report[J]. The Journal of Biomedical Research, 2022, 36(6): 440-445. doi: 10.7555/JBR.36.20220065
Citation: Mingzi Zhang, Qi Li, Yehong Sun. Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report[J]. The Journal of Biomedical Research, 2022, 36(6): 440-445. doi: 10.7555/JBR.36.20220065

Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report

doi: 10.7555/JBR.36.20220065
More Information
  • Corresponding author: Qi Li, Department of Internal Medicine-Oncology, Shenzhen Traditional Chinese Medicine Hospital, 1 Fuhua Road, Shenzhen, Guangdong 518033, China. E-mail: doctorliqi@126.com; Yehong Sun, Department of Pharmacy, Shenzhen Traditional Chinese Medicine Hospital, 1 Fuhua Road, Shenzhen, Guangdong 518033, China. Tel: +86-755-88605070, E-mail: syehong@163.com
  • Received: 2022-03-24
  • Revised: 2022-05-07
  • Accepted: 2022-05-13
  • Published: 2022-06-28
  • Issue Date: 2022-11-28
  • Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) plays an important role in cancer therapy. However, EGFR is highly expressed in the skin and gives rise to one of the most concerning issues for the EGFR-TKI treatment, namely skin toxicity. Antibiotics and corticosteroids are usually used to treat the EGFR inhibitor-associated skin rash, with prominent side effects over long-time use. Pien Tze Huang (PZH) Unguentum Compositum is a traditional product for external application which is made of traditional Chinese medicine and oil base. Herein, we reported the case of a 50-year-old man who presented with skin rash on the face, head, and back induced by an EGFR-TKI named erlotinib. By using PZH Unguentum Compositum, we observed that the skin rash was mitigated and eventually disappeared. This case report suggests that PZH Unguentum Compositum may be an effective therapy in treating skin rash caused by EGFR-TKI with fewer side effects.

     

  • CLC number: R275.9, Document code: B
    The authors reported no conflict of interests.
  • loading
  • [1]
    Jurišić V, Obradovic J, Pavlović S, et al. Epidermal growth factor receptor gene in non-small-cell lung cancer: the importance of promoter polymorphism investigation[J]. Anal Cell Pathol (Amst), 2018, 2018: 6192187. doi: 10.1155/2018/6192187
    [2]
    Jurisic V, Vukovic V, Obradovic J, et al. EGFR polymorphism and survival of NSCLC patients treated with TKIs: a systematic review and meta-analysis[J]. J Oncol, 2020, 2020: 1973241. doi: 10.1155/2020/1973241
    [3]
    Xia G, Zeng Y, Fang Y, et al. Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI[J]. Cancer Biol Med, 2014, 11(4): 270–276. doi: 10.7497/j.issn.2095-3941.2014.04.006
    [4]
    Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future[J]. Expert Rev Anticancer Ther, 2013, 13(6): 745–758. doi: 10.1586/era.13.47
    [5]
    Melosky B, Leighl NB, Rothenstein J, et al. Management of EGFR TKI-induced dermatologic adverse events[J]. Curr Oncol, 2015, 22(2): 123–132. doi: 10.3747/co.22.2430
    [6]
    Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor[J]. Jpn J Clin Oncol, 2016, 46(4): 291–298. doi: 10.1093/jjco/hyv207
    [7]
    Zhang X, Zhang Q, Huang L, et al. Pien-Tze-Huang attenuates neuroinflammation in cerebral ischaemia-reperfusion injury in rats through the TLR4/NF-κB/MAPK pathway[J]. Pharm Biol, 2021, 59(1): 826–837. doi: 10.1080/13880209.2021.1942926
    [8]
    Zeng M, Zhu J, Yang G. The clinical observation of Pien Tze Huang Unguentum Compositum Cream combined with Lankefuning on rosacea[J]. Chin J Aesthetic Med (in Chinese), 2012, 21(18): 291. http://www.cnki.com.cn/Article/CJFDTotal-MRYX201218293.htm
    [9]
    Zhu H, Li T, Du Y, et al. Pancreatic cancer: challenges and opportunities[J]. BMC Med, 2018, 16(1): 214. doi: 10.1186/s12916-018-1215-3
    [10]
    Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. Lancet Oncol, 2019, 20(5): 625–635. doi: 10.1016/S1470-2045(19)30035-X
    [11]
    Lee HJ, Jeong GH, Li H, et al. Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis[J]. Eur Rev Med Pharmacol Sci, 2021, 25(20): 6232–6244. doi: 10.26355/eurrev_202110_26993
    [12]
    Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) Tyrosine kinase inhibitors in oncology[J]. Drug Saf, 2019, 42(2): 181–198. doi: 10.1007/s40264-018-0772-x
    [13]
    Arrieta O, Vega-González MT, López-Macías D, et al. Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients[J]. Lung Cancer, 2015, 88(3): 282–288. doi: 10.1016/j.lungcan.2015.03.019
    [14]
    Chen Z. Pien Tze Huang (PZH) as a multifunction medicinal agent in traditional Chinese medicine (TCM): a review on cellular, molecular and physiological mechanisms[J]. Cancer Cell Int, 2021, 21(1): 146. doi: 10.1186/s12935-021-01785-3
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)

    Article Metrics

    Article views (191) PDF downloads(24) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return